继1月2日壁仞科技上市之后，2026年港股又迎来一批新股。 1月8日，智谱、天数智芯以及精锋医疗-B这3家公司正式登陆港交所。数据显示，3家公司的首日涨幅分别为13.17%、8.44%和30.90%。 | | 131.500 +15.300 +13.17% | | 118.542(CNY) | | | | 智谱 立即 2513 交易 | | --- | --- | --- | --- | --- | --- | --- | --- | | HKEX HKD 16:08:11 | | | | | | | 1 . . + | | 载 | -39.04% == | | -1.14万 | रेस | 0.00% 120日 | | 0.00% | | 死 | 132.000 | 1.11万 ( | 49 ) | 5日 | 0.00% 250日 | | 0.00% | | 委员 | 131.900 | 600 ( | 5) | 20日 | 0.00% 52周高 | | 0.00 | | 卒三 | 131.800 | 600 | 4) | 60日 | 0.00% 52周低 | | 0.00 | | 実ニ | 131.700 ...

重塑全球外科手术机器人的竞争格局。 在外科手术中，微创手术凭借侵入性低、创口微小、康复周期短、术后并发症少等多重临床优势，成为 当下愈发常见的首选手术方案。而机器人辅助微创手术又加速成为了行业主流趋势。不过，这一高端赛 道曾长期被海外品牌垄断，国产力量在市场中话语权较弱。 而来自深圳的精锋医疗，凭借超600项专利构建的技术壁垒和市场的认可，正逐步重塑全球外科手术机 器人的竞争格局。1月8日，精锋医疗正式登陆港股，开盘价59港元/股，开盘市值达230亿港元。 拥有超600项专利 精锋医疗成立于2017年，是医疗器械领域的领先手术机器人企业，专注于手术机器人的设计、研发与制 造。公司已构建起覆盖不同治疗场景、处于多研发阶段的产品矩阵，核心包含三类产品及在研项目：适 用于微创手术的多孔腔镜手术机器人、单孔腔镜手术机器人，以及面向无创手术的自然腔道手术机器 人。 其中，精锋多孔腔镜手术机器人与精锋单孔腔镜手术机器人为公司核心产品。前者是集成机器人技术、 成像技术与数字技术的微创辅助设备，应用范围覆盖泌尿科、妇科、普外科及胸外科；后者则通过单个 小切口或自然腔道实施微创手术，适配泌尿科、妇科、普外科等临床场景。 据弗若 ...

唯一一家系统布局医疗健康的早期投资机构。 将投中网设为"星标⭐"，第一时间收获最新推送 来源丨 投中网 1 月 8 日，深圳市精锋医疗科技股份有限公司（简称：精锋医疗 ® ） 成功登陆港交所，发行价为每股43.24港元，股票代码：2675.HK。这家公司上 市首日开盘涨超38%，市值达到230亿港元。 作为一家医疗器械行业的先进手术机器人公司，精锋医疗 ® 拥有多孔腔镜手术机器人和单孔腔镜手术机器人。 2025 年 10 月，精锋医疗 ® 自主研发 的精锋 单孔腔镜手术机器人 SP1000 及单多孔手术机器人超级系统 MSP2000 正式获得欧盟 CE 认证（ MDR ）。这标志着全球首个 " 单多孔一体 化 " 手术机器人平台成功进入国际市场，开启了由中国智慧定义的 " 全能微创 " 手术新时代。 一路走来，这家由天津大学校友王建辰和高元倩创立的公司得到了联想之星、联想控股、君联资本、红杉中国、博裕投资等众多知名投资者的支持。其 中，联想之星是股东里面唯一一家系统布局医疗健康领域的早期投资机构。按照230 亿港元市值粗略计算，两笔共 2800 万元的投资已经让联想之星获 得了 近20 倍的账面回报。 "精锋 ...

Group 1 - The company, 精锋医疗-B (02675), plans to conduct an IPO from December 30, 2025, to January 5, 2026, issuing 27.72 million H-shares at a price of HKD 43.24 per share, aiming to raise nearly HKD 1.2 billion [1] - The company is an advanced surgical robotics firm in the medical device industry, focusing on the design, development, and manufacturing of surgical robots, with products in various stages of research and development [1][2] - The company has received significant interest in its IPO, with a reported margin loan of HKD 478.7 billion and an oversubscription rate of 398 times for the public offering [1] Group 2 - The product portfolio includes two core self-developed products: the 精锋多孔腔镜手术机器人 (multi-port laparoscopic surgical robot) and the 精锋单孔腔镜手术机器人 (single-port laparoscopic surgical robot), along with a non-core product, the 精锋支气管镜机器人 (bronchoscopic robot) [2] - The company has established cornerstone investment agreements with several investors, including OrbiMed Genesis and Tencent, agreeing to subscribe for a total of USD 75 million worth of shares under certain conditions [2] - The net proceeds from the global offering are estimated to be approximately HKD 1.1166 billion, with allocations planned for R&D (42%), commercialization (20%), capacity expansion (10%), other products (8%), strategic acquisitions (10%), and working capital (10%) [3]

Group 1 - The company, Jingfeng Medical-B (02675), plans to conduct a global offering of 27.72 million H-shares from December 30, 2025, to January 5, 2026, with a share price of HKD 43.24 per share [1] - The company specializes in advanced surgical robots, having developed products for minimally invasive and non-invasive surgeries, including the multi-port and single-port laparoscopic surgical robots [1] - The company has reported a significant increase in revenue, from RMB 48 million for the year ending December 31, 2023, to RMB 160 million for the year ending December 31, 2024 [2] Group 2 - The company has incurred operating losses during the reporting periods, with net losses of RMB 213 million, RMB 218.5 million, RMB 133 million, and RMB 89.1 million for the respective periods due to R&D expenses [2] - The company has entered cornerstone investment agreements with several investors, including OrbiMed Genesis and Tencent, agreeing to subscribe for shares totaling USD 75 million under certain conditions [3] - The net proceeds from the global offering are expected to be approximately HKD 1.1166 billion, with allocations for R&D, commercialization, capacity expansion, and potential strategic acquisitions [4]

Group 1: Market Overview - The Hang Seng Index (HSI) has shown a positive trend, closing at 25,801 points, up 111 points or 0.4%, marking its fourth consecutive day of gains [3] - The market experienced a high opening, reaching 25,859 points before facing resistance, and later fluctuated around the 20-day moving average [3] - The total market turnover was approximately HKD 169.77 billion, with a net inflow of HKD 3.125 billion from northbound trading [3] Group 2: Macro & Industry Dynamics - The Hong Kong government plans to focus on developing the gold market in 2025, aiming to establish an international gold trading center and enhance cooperation with Shanghai and Shenzhen [6][7] - The Hong Kong Stock Exchange is currently processing over 300 listing applications, indicating sustained market momentum, with expectations for continued interest from international investors [7] - The Mandatory Provident Fund (MPF) is projected to achieve a return rate of 15.35% for the year 2025, which would be the sixth-best annual performance in its 25-year history, translating to an estimated investment income of HKD 200.9 billion [8] Group 3: Company News - Country Garden (碧桂园) announced a share placement at HKD 0.4 per share, representing a discount of approximately 12.09% from the previous closing price, which will increase its issued share capital by about 0.48% [10] - Precision medical technology company, Jingfeng Medical Technology, has passed the listing hearing with plans to list on the Hong Kong main board, focusing on surgical robots [11] - GeneTech (吉因加科技) has submitted a listing application to the Hong Kong Stock Exchange, aiming to leverage AI in precision medicine and address unmet medical needs in China [12]

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) has passed the listing hearing on the Hong Kong Stock Exchange, with Morgan Stanley and GF Securities as joint sponsors [1] Company Overview - Precision Medical is an advanced surgical robotics company in the medical device industry, focused on the design, development, and manufacturing of surgical robots. The company has three products at different stages of research and development, targeting the market potential of surgical robots, including multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots for minimally invasive procedures [3] Product Portfolio - The product lineup includes two core self-developed products: the Precision Multi-Port Laparoscopic Surgical Robot and the Precision Single-Port Laparoscopic Surgical Robot. Additionally, the company has the Precision Bronchoscopy Robot, which is not a core product. The Multi-Port Laparoscopic Surgical Robot is designed for minimally invasive surgeries across urology, gynecology, general surgery, and thoracic surgery, while the Single-Port Laparoscopic Surgical Robot is used for surgeries through a single small incision or natural orifice, applicable in urology, gynecology, and general surgery [3] Market and Regulatory Achievements - Precision Medical is the first company in China and the second globally to obtain regulatory approval for multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots. The company received its first registration approvals from the National Medical Products Administration for these products in December 2022, November 2023, and January 2025, respectively [4] Financial Performance - For the fiscal years ending June 30, 2023, and 2024, Precision Medical reported revenues of approximately RMB 48.04 million and RMB 160 million, respectively. The company incurred losses of approximately RMB 213 million and RMB 219 million for the same periods. The financial data indicates a significant investment in research and development, with R&D expenses of RMB 171.23 million and RMB 226.25 million for the respective years [4][7]

Core Viewpoint - The third Global Medical Robotics Conference 2025, themed "MedRobot Next | Next Stop Technology Future," focuses on the systematic upgrade of intelligent surgical systems, the construction of a full-chain ecosystem, and global pathways in the surgical robotics industry [5][7]. Event Details - The event will take place on September 5-6, 2025, at the Zhongguancun Innovation Demonstration Zone Exhibition Center in Beijing [7]. - Pre-registration is free, and attendees will receive discount codes upon the opening of the registration system [2]. Participating Companies - Confirmed participants include manufacturers from various surgical robotics sectors such as minimally invasive robots, orthopedic robots, ophthalmic robots, and vascular intervention robots [2][5]. Conference Themes - The conference will cover several key themes, including: - **Technological Systems and Intelligent Evolution** [8] - **Commercialization and Hospital System Implementation** [8] - **Global Strategy and International Expansion Paths** [9] Key Topics of Discussion - The conference will address critical topics such as: - AI integration in surgical robots to enhance autonomy and system collaboration [10] - The challenges of integrating surgical robots with hospital systems [10] - Global market comparisons and commercialization pathways for surgical robots [10] - The importance of building a sustainable and credible robot brand recognized by doctors [10] - The exploration of day surgery and grassroots market opportunities for robotic solutions [10] Awards and Recognition - The MedRobot annual awards have become one of the most anticipated technical awards in the Chinese medical robotics field, recognizing significant contributions and innovations [16]. Industry Insights - The conference aims to redefine the future of hospitals through robotic technology, emphasizing the need for collaboration among manufacturers, component suppliers, algorithm developers, and clinical teams [17].